AIM: To investigate the risk factors about recrudescence of retinopathy of prematurity(ROP)after anti-VEGF treatment. METHODS: A retrospective study about all the infants diagnosed with ROP and treated with anti-VEGF from June 2016 to October 2019 in our hospital. They were divided into recrudescence group(8 cases)and non- recrudescence group(48 cases). The relationship between various clinical risk factors and the recrudescence of ROP after anti-VEGF treatment were considered. Those risk

more »

... s included birth weight, gestational age, thrombocytosis, anemia, coagulation disorder, sepsis, bronchopulmonary dysplasia, neonatal respiratory distress syndrome, asphyxia, pneumonia, intracranial hemorrhage, patent foramen ovale, and patency ductus arteriosus. RESULTS: According to single-factor analysis, birth weight and intracranial hemorrhage showed statistically significant differences between recrudescence group and non-recrudescence group. Logistic regression analysis showed low birth weight(OR=9.800, P=0.039)and intracranial hemorrhage(OR=17.571, P=0.002)had relationship with recrudescence of ROP after anti-VEGF.CONCLUSION: Low birth weight(<1 000g)and intracranial hemorrhage are the risk factors about recrudescence of ROP after anti-VEGF.